BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daxor Corporation (DXR) Announces Filing of Form N-CSR for June 30, 2012 and Volumex Kit Sales for the First Six Months of 2012


9/4/2012 9:24:28 AM

NEW YORK, NY--(Marketwire - September 04, 2012) -

Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, filed a Form N-CSR today disclosing its schedule of portfolio holdings as of June 30, 2012. Copies of the form have been mailed to the Company's shareholders. The Company also disclosed its results for the six months ended June 30, 2012 in the Form N-CSR.

For the six months ended June 30, 2012, the Company's revenue from the sale of Volumex Kits increased by 3% from the same period in 2011. There were 66 Blood Volume Analyzers in service at June 30, 2012 versus 58 instruments at June 30, 2011. There is additional disclosure regarding the Company's Operating Division in the Form N-CSR which was filed today.

The Company recently received a refund of federal taxes of approximately $2,090,000. The loss for the year ended December 31, 2011 was used to offset taxes paid for the years ended December 31, 2010 and 2009 which generated the refund.

The Company used part of the proceeds from the tax refund to pay a dividend of $0.10 per share on August 24, 2012. Management elected to use the remainder of the proceeds to help fund its medical instrumentation and biotechnology operations.

Dr. Joseph Feldschuh, the President of Daxor, said: "We don't know if this improvement in the sale of Volumex Kits will continue. We realize there are no guarantees but remain hopeful that members of the medical community will understand the need for measuring patient's blood volume precisely rather than using surrogate tests and clinical guesstimates which can be grossly inaccurate. The precise knowledge of a patient's blood volume is essential for optimally treating critically ill and post operative patients."


Contact Information:
Daxor Corporation:
David Frankel
212-330-8504
Chief Financial Officer
dfrankel@daxor.com

Diane Meegan
212-330-8512
Investor Relations
dmeegan@daxor.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES